News | December 13, 2007

PCI Guideline Update Stresses Long-Term Anticoagulant Therapy After Drug-Eluting Stent Treatment

December 14, 2007 - According to a guideline update published online today in the journals of the Society for Cardiovascular Angiography and Interventions (SCAI), American College of Cardiology (ACC) and American Heart Association (AHA), patients treated with drug-eluting stents must take a combination of aspirin and the clot-reducing drug clopidogrel for at least one year, and possibly longer, after stent implantation.

Percutaneous coronary intervention (PCI), or angioplasty is a proven therapy for stopping heart attack and relieving painful symptoms of heart disease that result from arteries narrowed or blocked by the build-up of fatty deposits. The guideline update incorporates findings from research published relatively recently on the role of PCI in the spectrum of care for heart disease patients.

"For most patients suffering a heart attack, angioplasty and implantation of a stent is a life-saving procedure," said SCAI President Dr. Bonnie Weiner. "However, both patients and the medical community need to understand how essential dual anticoagulant therapy is after receiving a drug-eluting stent. That's the purpose of this update - to stress this and other evidence published relatively recently."

The update specifically addresses findings from studies published through late 2006. One of the concerns that arose during this period was about a slightly higher risk of blood clots forming inside drug-eluting stents. These clots are a rare but serious complication of drug-eluting stents and must be prevented with a strict regimen of aspirin plus the clot-reducing drug clopidogrel for at least one year after the artery is opened with a stent.

"By emitting tiny amounts of medication, drug-eluting stents reduce the regrowth of scar tissue and other build-up that could renarrow the artery, creating a need for a repeat angioplasty," explained Dr. Weiner. "While we don't want to understate the precautions that should be taken to prevent clots, we also want to factor in the benefits of these newer devices.

"If there are doubts about whether the patient can stay on the dual-antiplatelet therapy for at least one year, then a bare metal stent is probably the better choice," stressed Dr. Weiner. "We want to encourage physicians to think about the patient's history with compliance to drug therapy as well as other potential obstacles, such as planned surgeries, that might lead them to not take their aspirin and clopidogrel. In those cases, the update calls for a bare metal stent or balloon angioplasty with provisional stent implantation."

For more information: www.scai.org

Related Content

Resolute Onyx Stent With Improved Radiographic Visibility Found to Be Safe and Effective
News | Stents Drug Eluting | October 01, 2018
October 1, 2018 — Recent results from the BIONYX randomized clinical study showed the novel, thin-strutted, polymer-c
Boston Scientific Receives FDA Approval for Eluvia Drug-Eluting Vascular Stent
Technology | Stents Drug Eluting | October 01, 2018
Boston Scientific announced that the U.S. Food and Drug Administration (FDA) has approved its Premarket Approval (PMA)...
Eluvia Drug-Eluting Stent Demonstrates Superior Patency in IMPERIAL Trial
News | Stents Drug Eluting | September 26, 2018
Positive 12-month data from the late-breaking IMPERIAL trial was presented at the 2018 Transcatheter Cardiovascular...
Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
Overlay Init